Accuray Incorporated  

(Public, NASDAQ:ARAY)   Watch this stock  
Find more results for ARAY
-0.03 (-0.43%)
Real-time:   9:38AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.95 - 7.06
52 week 4.80 - 10.01
Open 6.95
Vol / Avg. 0.00/962,931.00
Mkt cap 559.09M
P/E     -
Div/yield     -
EPS -0.40
Shares 79.87M
Beta 1.68
Inst. own 100%
Jan 25, 2016
Q2 2016 Accuray Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 19, 2015
Accuray Inc Annual Shareholders Meeting
Nov 10, 2015
Accuray Inc at Credit Suisse Healthcare Conference - Webcast
Oct 29, 2015
Q1 2016 Accuray Inc Earnings Call - Webcast
Oct 29, 2015
Q1 2016 Accuray Inc Earnings Release
Sep 17, 2015
Accuray Inc at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin -14.53% -10.59%
Operating margin -8.07% -5.05%
EBITD margin - 0.09%
Return on average assets -11.21% -8.33%
Return on average equity -74.69% -46.13%
Employees 1,010 -
CDP Score - -


1310 Chesapeake Ter
SUNNYVALE, CA 94089-1100
United States - Map
+1-408-7164600 (Phone)
+1-408-7164601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Officers and directors

Louis J Lavigne Jr Independent Chairperson of the Board
Age: 67
Bio & Compensation  - Reuters
Joshua Levine President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Kevin Waters Chief Financial Officer, Senior Vice President
Age: 38
Bio & Compensation  - Reuters
Kelly Londy Chief Operating Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Alaleh Nouri Senior Vice President, General Counsel, Corporate Secretary
Age: 35
Bio & Compensation  - Reuters
Jack Goldstein Ph.D. Independent Director
Age: 92
Bio & Compensation  - Reuters
Richard R. Pettingill Independent Director
Age: 66
Bio & Compensation  - Reuters
Emad Rizk M.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
Robert S. Weiss Independent Director
Age: 68
Bio & Compensation  - Reuters
Dennis L. Winger Independent Director
Age: 67
Bio & Compensation  - Reuters